表紙:精神病治療薬の世界市場 (2021-2028年)
市場調査レポート
商品コード
972306

精神病治療薬の世界市場 (2021-2028年)

Global Psychotherapeutic Drugs Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
精神病治療薬の世界市場 (2021-2028年)
出版日: 2021年07月12日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の精神病治療薬市場の成長は、情緒障害および精神障害の発生率の上昇、精神病治療薬に関する人々の意識の高まり、研究開発プロセスへの注目の高まりによって推進されています。しかし、研究開発への高額な投資コストは市場の成長を妨げる可能性があります。加えて、精神病治療薬による眠気、不眠症、かすみ目などの副作用は、予測期間中に市場を抑制する可能性があります。

当レポートでは、世界の精神病治療薬市場について調査し、市場の概要、各セグメントおよび地域別の市場分析と予測、競合情勢の分析、主要企業のプロファイルなどを提供しています。

目次

第1章 世界の精神病治療薬市場:調査範囲・手法

  • 調査手法
  • 調査目的・調査範囲

第2章 世界の精神病治療薬市場:市場定義・概要

第3章 世界の精神病治療薬市場:エグゼクティブサマリー

  • 市場内訳:医薬品クラス別
  • 市場内訳:アプリケーション別
  • 市場内訳:流通チャネル別
  • 市場内訳:地域別

第4章 世界の精神病治療薬市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の精神病治療薬市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 医療費償還分析
  • アンメットニーズ

第6章 世界の精神病治療薬市場:COVID-19分析

  • 市場におけるCovid-19の分析
    • COVID-19:以前の市場シナリオの前
    • COVID-19:現在の市場シナリオ
    • COVID-19:以降または将来のシナリオ
  • Covid-19における価格のダイナミクス
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の精神病治療薬市場:医薬品クラス別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):医薬品クラス別
    • 市場魅力指数:医薬品クラス別
  • 抗精神病薬
  • 抗うつ薬
  • 精神病複合薬
  • 抗そう薬
  • 抗不安薬

第8章 世界の精神病治療薬市場:アプリケーション別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):アプリケーション別
    • 市場魅力指数:アプリケーション別
  • 統合失調症
  • 認知症
  • 双極性うつ病
  • 単極性うつ病

第9章 世界の精神病治療薬市場:流通チャネル別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):流通チャネル別
    • 市場魅力指数:流通チャネル別
  • 病院薬局
  • 薬局
  • その他

第10章 世界の精神病治療薬:地域別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):地域別
    • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析(%):医薬品クラス別
    • 市場規模分析・前年比成長分析(%):アプリケーション別
    • 市場規模分析・前年比成長分析(%):流通チャネル別
    • 市場規模分析・前年比成長分析(%):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第11章 世界の精神病治療薬:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第12章 世界の精神病治療薬:企業プロファイル

  • Allergan plc
  • Eli Lilly & Co.
  • Johnson & Johnson
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Astellas Pharma, Inc.
  • Abbott Laboratories
  • Otsuka America Pharmaceutical, Inc.

第13章 重要考察

第14章 DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH2841

Market Overview

The global Psychotherapeutic drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Psychotherapeutic drugs are used to treat several types of mental disorders such as schizophrenia, bipolar disorder, anxiety, and depression. Several types of psychotherapeutic drugs are available in the market for the treatment of severe mental illnesses and behavioral disorders.

Market Dynamics

The global Psychotherapeutic drugs market market growth is driven by the rising incidences of emotional and mental diseases, rise in the awareness among people regarding psychotherapeutic drugs, increasing focus on research and development process.

High prevalence of mental disorders and depression globally, is expected to drive the growth in the forecast period

High prevalence of mental disorders and depression globally, increase in risk of depression owing to poverty, unemployment, death of loved ones, or relationship problems are the key factors driving the global psychotherapeutic drugs market. According to the World Health Organization, over 300 million people, nearly 4.4% of the global population, suffered from depression in 2015. Additionally, the estimated number of people living with depression has increased by 18.4% from 2005 to 2015. Introduction of new psychotherapeutic drugs in the market, owing to the increase in R&D investment budgets, demand for cost-effective antipsychotic drugs, and therapeutic application of psychotherapeutic drugs are likely to boost demand for psychotherapeutic drugs during the forecast period.

Increase in hyperlipidemia cases expected to drive the market growth

Globally, development of advance and efficient technology, rising incidences of emotional and mental diseases, rise in the awareness among people regarding psychotherapeutic drugs, increasing focus on research and development process, and growth in incidences of mental disorders such as schizophrenia and bipolar disorder are the prime growth drivers of psychotherapeutic drugs market..

For instance, nearly one in five (18.5%) Americans experiences mental health problems each year. In the U.S., in 2015, an estimated 9.8 million, which equated to nearly 4.8% of all adults (over 18 years of age) had serious mental disorders. Presence of multiple psychotherapy associations such as the United Kingdom Council for Psychotherapy, the British Psychoanalytic Council, and the British Association for Counselling and Psychotherapy drives the market growth.

High investment costs in R&D is likely to hinder the market growth

However, side effects such as drowsiness, insomnia, and blurred vision caused by psychotherapeutic drugs are likely to restrain the market during the forecast period.

COVID-19 Impact Analysis

In the wake of the COVID-19 viral pandemic, the world will likely experience a serious mental health crisis. Even as the first wave of infection passes, stressors associated with COVID-19, including self-quarantine, social distancing, job loss, and threat of illness, will persist. These factors can be expected to have a significant impact on the human psyche and contribute to a secondary mental health epidemic. Thus the pendamic will drive the market in the forecast period.

Segment Analysis

Antipsychotic drugs, segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The global market for antipsychotic drugs is witnessing significant traction owing to the global rise in prevalence of psychotic disorders such as bipolar disorder, schizophrenia, delusions, hallucinations, and very severe depression (called "psychotic depression"). Recent studies have stated that antipsychotics are one of the top-selling and most widely prescribed drugs for managing psychotic conditions in the United States. Although earlier prescribed only for such psychotic conditions, a vast variety of antipsychotics are also prescribed as a supplement to antidepressant medications and for routine complaints such as insomnia. Records demonstrate that antipsychotics such as Abilify are outselling other drug varieties and are becoming one of the key and high-profit drug Classses of the pharma industry.

According to the Anxiety and Depression Association of America, Anxiety disorders are the most common mental illness in the United States, affecting 40 million adults in the United States age 18 and older, or 18.1% of the population every year. Nearly one-half of those diagnosed with depression are also diagnosed with an anxiety disorder.

World Health Organization (WHO) has recommended mental health action plan to promote mental health and preventing mental disorders in the member states. In addition, according to the key facts published by WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, worldwide. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience the ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable

The Schizophrenia are expected to dominate the psychotherapeutic drugs market during the forecast period

Schizophrenia is a serious mental disorder and is affecting the large number of people across the globe. The disease is mainly characterized by the distortions in thinking, emotions, and sense of self and behavior. World Health Organization has stated that around 23 million people across the globe are affected by this disorder among which 12 million are male and 9 million are females. National Institute of Mental Health has stated that the prevalence of Schizophrenia and related symptoms is around 0.25% and 0.64% and this is increasing rapidly. This rise in the prevalence of the disease is contributing to the market growth.

As the disease is serious and it increases the chances of early death if not treated properly, there is a growing focus of companies to come up with novel drugs for the treatment of this disease. Currently, there are several FDA approved drugs available in the market. For instance, Chlorpromazine, Aripiprazole, Olanzapine, etc. and there is new drug approval every year, which is expected to drive the market growth over the forecast period.

The hospital pharmacy are expected to dominate the psychotherapeutic drugs market during the forecast period

The hospital pharmacies held the largest share in the Psychotherapeutic drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global psychotherapeutic drugs market

North America region is dominating the global Psychotherapeutic drugs market accounted for the largest market share in 2020. High prevalence of depression and mental disorders, high per capita health care expenditure, and favorable medical reimbursement policies are the key factors likely to contribute to the growth of the psychotherapeutic drugs market in North America during the forecast period. According to the Anxiety and Depression Association of America, over 18.1% of the population of the U.S. are diagnosed with mental disorders each year.

Competitive Landscape

The psychotherapeutic drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Eli Lilly & Co., Johnson & Johnson, Pfizer, Inc., Bristol-Myers Squibb Company, Allergan, GlaxoSmithKline plc, AstraZeneca plc, and Astellas Pharma, Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the psychotherapeutic drugs market globally.

Digestive Enzymes Market Key Companies to Watch

Allergan Plc.

Overview: Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products.

Product Portfolio: The Company's portfolio comprised of pharmaceutical products of specialties for ophthalmologic care, neuromuscular, dermatological and urologic medical devices primarily facial aesthetics products, breast plastic products.

Why Purchase the Report?

  • Visualize the composition of the psychotherapeutic drugs market segmentation by drug Class, application, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in psychotherapeutic drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of psychotherapeutic drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global psychotherapeutic drugs market report would provide an access to an approx. 62 market data table, 55 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Psychotherapeutic Drugs Market - By Drug Class

  • Antipsychotic Drugs
  • Antidepressants
  • Psychotherapeutic combinations
  • Animaniacs
  • Anxiety Drugs

Global Psychotherapeutic Drugs Market - By Application

  • Schizophrenia
  • Dementia
  • Bipolar
  • Unipolar depression

Global Psychotherapeutic Drugs Market - By Distribution Channel

  • Hospital Pharmacy
  • Pharmacy Stores
  • Other

Global Psychotherapeutic Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Psychotherapeutic Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Psychotherapeutic Drugs Market - Market Definition and Overview

3. Global Psychotherapeutic Drugs Market - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Application
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Psychotherapeutic Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. High prevalence of mental disorders and depression globally
      • 4.1.1.2. Increase in hyperlipidemia cases expected to drive the market growth
    • 4.1.2. Restraints:
      • 4.1.2.1. High investment costs in R&D is likely to hinder the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Psychotherapeutic Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Psychotherapeutic Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Psychotherapeutic Drugs Market - By Drug Classs

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Classs Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Antipsychotic Drugs *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Antidepressants
  • 7.4. Psychotherapeutic combinations
  • 7.5. Antimaniacs
  • 7.6. Anxiety Drugs

8. Global Psychotherapeutic Drugs Market - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Schizophrenia *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Dementia
  • 8.4. Bipolar
  • 8.5. Unipolar depression

9. Global Psychotherapeutic Drugs Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Pharmacy Stores
  • 9.4. Other

10. Global Psychotherapeutic Drugs Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Classs
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Classs
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Classs
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Classs
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Classs
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Psychotherapeutic Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start Up Companies

12. Global Psychotherapeutic Drugs Market- Company Profiles

  • 12.1. Allergan plc *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Eli Lilly & Co.
  • 12.3. Johnson & Johnson
  • 12.4. Pfizer, Inc.
  • 12.5. Bristol-Myers Squibb Company
  • 12.6. GlaxoSmithKline plc
  • 12.7. AstraZeneca plc
  • 12.8. Astellas Pharma, Inc.
  • 12.9. Abbott Laboratories
  • 12.10. Otsuka America Pharmaceutical, Inc.

LIST NOT EXHAUSTIVE

13. Global Psychotherapeutic Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us